Printer Friendly

NYU Langone Enrolls Patients in Clinical Trial for COVID-19 Antibody Therapy.

M2 PHARMA-June 1, 2020-NYU Langone Enrolls Patients in Clinical Trial for COVID-19 Antibody Therapy

(C)2020 M2 COMMUNICATIONS

NYU Langone has enrolled patients as part of clinical trial testing to determine whether monoclonal antibody treatment can safely reduce the severity of COVID-19, the company said.

The experimental treatment consists of identical copies of an antibody, a blood protein related to those that occur naturally as part of the human immune system, researchers say.

Eli Lilly and company started clinical trials with NYU Grossman School of Medicine among the first centres to enroll patients nationally. The phase 1 clinical trial is designed primarily to measure the safety and side effects of the treatment, called LY-CoV555, in patients hospitalised due to infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Lilly is developing the treatment in collaboration with AbCellera, which used its proprietary drug discovery technology to analyse antibodies from patients that recovered from COVID-19.

They sought to find the antibodies which most tightly attached to the virus in places known to block its ability to infect human cells (neutralising antibodies).

Beyond emergency and supportive care, there are currently no FDA-licensed treatment options for coronavirus disease 2019 (COVID-19), the infection caused SARS-CoV-2.

Along with Cedars-Sinai Medical Centre and Emory University, NYU Langone was chosen as one of the first trial centres because it is known for its clinical trials expertise and capacity to rapidly initiate crucial studies.

The current treatment candidate was chosen because it is shaped to interact with the spike proteins used by SARS-CoV-2 to attach to human cell surfaces, the first step in invading cells, say the investigators. Viruses must enter cells to multiply and the study treatment is meant to prevent such entry and neutralise the virus.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2020 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 1, 2020
Words:300
Previous Article:Well Beyond Tech Company Launches Free App to Combat COVID-19 in Developing World.
Next Article:Cigna Extends Relief Efforts to Holders of Medicare Advantage, Individual and Family Plans for COVID-19.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters